Zymed Co., Ltd. (hereinafter referred to as Zymed)'s 'Fundus-based Cardiovascular AI Evaluation' has been officially introduced as a screening item by the Korea Health Management Association (hereinafter referred to as Medicheck) and is being implemented in 17 branches nationwide.
Starting this year, examinees who have undergone fundus examinations at 17 Medicheck branches nationwide can receive a ‘fundus-based cardiovascular AI evaluation’ at a reasonable cost. It is linked to the fundus photography equipment and provides real-time AI interpretation and opinions, allowing examinees to easily check the results, and medical staff can also quickly guide examinees to additional tests they need through this solution, enabling efficient diagnosis and consultation.
Zymed, headquartered in the 'BT·IT Convergence Center' of Seoul Biohub, a digital healthcare startup hub, is showcasing a technology that predicts health conditions in advance through non-invasive and simple tests, breaking away from the existing disease-centered checkups through a new concept called 'Opportunistic Diagnosis'. The 'Fundus-based Cardiovascular AI Assessment' developed by Zymed is a technology that evaluates the risk of carotid arteriosclerosis and coronary arteriosclerosis with just a simple fundus photograph and suggests the need for additional detailed tests. Its accuracy and reliability have been verified through a joint study with Medicheck involving over 100,000 people.
The 'Fundus-based Cardiovascular AI Assessment' solution is the only medical AI that predicts carotid arteriosclerosis and coronary arteriosclerosis 'simultaneously' using fundus photography, a non-invasive examination. It is an opportunistic diagnosis AI solution that evaluates the risk of atherosclerosis in areas other than the eyes through fundus photography that captures the retina and blood vessels of the eye, and can easily identify high-risk groups for cardiovascular disease that require additional precise examinations such as carotid artery ultrasound or cardiac CT. The risk of arteriosclerosis on the results printed after the examination can be used to diagnose the examinee's cardiovascular disease risk early, and it serves as a basis for providing more thorough chronic disease management services.
Zymed is pioneering a new field in the health screening market with this solution. The paper on the core technology of 'fundus-based cardiovascular AI evaluation' was published in the Journal of the American Academy of Ophthalmology and has been internationally verified, and is currently undergoing a new medical technology assessment deferral procedure for prescriptions for non-reimbursement at medical institutions.
In addition to the fundus-based AI solution, Zymed plans to expand its AI product line to various areas of opportunity screening by introducing the 'Explainable AI for Counterexample Generation' technology that can explain the interpretation process of AI, and the 'Auditing AI' technology that efficiently searches for the optimal new digital biomarker by simultaneously evaluating accuracy and explainability. Zymed is meeting the needs of the medical market through its diversified AI medical device product line and strengthening its position in the domestic and international healthcare markets.
- See more related articles
You must be logged in to post a comment.